Razoxane and Dexrazoxane - Two Multifunctional Agents: Experimental and Clinical Results

0 valoración promedio
( 0 valoraciones por Goodreads )
 
9789048191673: Razoxane and Dexrazoxane - Two Multifunctional Agents: Experimental and Clinical Results

Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of pathological blood vessels. Razoxane potentiates radiotherapy especially in the treatment of soft tissue sarcomas and gastrointestinal neoplasms. They protect normal tissues against toxic chemicals, e.g. the myocardium against anthracyclines or subcutaneous tissue against injuries caused by incidental extravasations of anthracyclines. Dexrazoxane is the only drug approved by the FDA/EMEA for the specific purpose of preventing cardiac damage when giving the widely used and effective antitumor anthracyclines. The reduction of cardiotoxicity is achieved without response reduction or reducing of time to progression of tumors. While the full analysis of their actions at the molecular level is not yet completely understood, it seems most likely that it is via an inhibition on the topoisomerase II a. Moreover, the drugs have the ability to chelate several metals including iron, copper or zinc. The protection of normal tissues is nowhere more important than that of brain, and there are indications that the proteins thought to be responsible for the ravages of Alzheimer´s disease could be stabilized by one or both these drugs.

"Sinopsis" puede pertenecer a otra edición de este libro.

Los mejores resultados en AbeBooks

1.

Hellmann, Kurt (edt); Rhomberg, Rhomberg; Rhomberg, Walter (edt)
ISBN 10: 904819167X ISBN 13: 9789048191673
Nuevos Cantidad: 2
Librería
GreatBookPrices
(Columbia, MD, Estados Unidos de America)
Valoración
[?]

Descripción Estado de conservación: New. Nº de ref. de la librería 9526883-n

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 163,60
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 2,25
A Estados Unidos de America
Destinos, gastos y plazos de envío

2.

Editorial: Springer, Netherlands (2010)
ISBN 10: 904819167X ISBN 13: 9789048191673
Nuevos Tapa dura Cantidad: 1
Librería
The Book Depository US
(London, Reino Unido)
Valoración
[?]

Descripción Springer, Netherlands, 2010. Hardback. Estado de conservación: New. 2011 ed.. Language: English . Brand New Book. Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of pathological blood vessels. Razoxane potentiates radiotherapy especially in the treatment of soft tissue sarcomas and gastrointestinal neoplasms. They protect normal tissues against toxic chemicals, e.g. the myocardium against anthracyclines or subcutaneous tissue against injuries caused by incidental extravasations of anthracyclines. Dexrazoxane is the only drug approved by the FDA/EMEA for the specific purpose of preventing cardiac damage when giving the widely used and effective antitumor anthracyclines. The reduction of cardiotoxicity is achieved without response reduction or reducing of time to progression of tumors. While the full analysis of their actions at the molecular level is not yet completely understood, it seems most likely that it is via an inhibition on the topoisomerase II a. Moreover, the drugs have the ability to chelate several metals including iron, copper or zinc. The protection of normal tissues is nowhere more important than that of brain, and there are indications that the proteins thought to be responsible for the ravages of Alzheimer s disease could be stabilized by one or both these drugs. Nº de ref. de la librería LIB9789048191673

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 165,92
Convertir moneda

Añadir al carrito

Gastos de envío: GRATIS
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

3.

Editorial: Springer, Netherlands (2010)
ISBN 10: 904819167X ISBN 13: 9789048191673
Nuevos Tapa dura Cantidad: 1
Librería
The Book Depository
(London, Reino Unido)
Valoración
[?]

Descripción Springer, Netherlands, 2010. Hardback. Estado de conservación: New. 2011 ed.. Language: English . Brand New Book. Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of pathological blood vessels. Razoxane potentiates radiotherapy especially in the treatment of soft tissue sarcomas and gastrointestinal neoplasms. They protect normal tissues against toxic chemicals, e.g. the myocardium against anthracyclines or subcutaneous tissue against injuries caused by incidental extravasations of anthracyclines. Dexrazoxane is the only drug approved by the FDA/EMEA for the specific purpose of preventing cardiac damage when giving the widely used and effective antitumor anthracyclines. The reduction of cardiotoxicity is achieved without response reduction or reducing of time to progression of tumors. While the full analysis of their actions at the molecular level is not yet completely understood, it seems most likely that it is via an inhibition on the topoisomerase II a. Moreover, the drugs have the ability to chelate several metals including iron, copper or zinc. The protection of normal tissues is nowhere more important than that of brain, and there are indications that the proteins thought to be responsible for the ravages of Alzheimer s disease could be stabilized by one or both these drugs. Nº de ref. de la librería LIB9789048191673

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 177,97
Convertir moneda

Añadir al carrito

Gastos de envío: GRATIS
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

4.

Hellmann, Kurt (EDT)/ Rhomberg, Walter (EDT)
Editorial: Springer 2010-10-06 (2010)
ISBN 10: 904819167X ISBN 13: 9789048191673
Nuevos Cantidad: 2
Librería
Chiron Media
(Wallingford, Reino Unido)
Valoración
[?]

Descripción Springer 2010-10-06, 2010. Estado de conservación: New. Brand new book, sourced directly from publisher. Dispatch time is 24-48 hours from our warehouse. Book will be sent in robust, secure packaging to ensure it reaches you securely. Nº de ref. de la librería NU-LBR-00856138

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 185,60
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 3,39
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

5.

WALTER RHOMBERG
Editorial: Springer (2010)
ISBN 10: 904819167X ISBN 13: 9789048191673
Nuevos Tapa dura Cantidad: 1
Librería
Herb Tandree Philosophy Books
(Stroud, GLOS, Reino Unido)
Valoración
[?]

Descripción Springer, 2010. Hardback. Estado de conservación: NEW. 9789048191673 This listing is a new book, a title currently in-print which we order directly and immediately from the publisher. For all enquiries, please contact Herb Tandree Philosophy Books directly - customer service is our primary goal. Nº de ref. de la librería HTANDREE0389395

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 179,93
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 9,07
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

6.

Walter Rhomberg (editor), Kurt Hellmann (editor)
Editorial: Springer Netherlands 2010-08-01, Dordrecht (2010)
ISBN 10: 904819167X ISBN 13: 9789048191673
Nuevos Tapa dura Cantidad: 1
Librería
Blackwell's
(Oxford, OX, Reino Unido)
Valoración
[?]

Descripción Springer Netherlands 2010-08-01, Dordrecht, 2010. hardback. Estado de conservación: New. Nº de ref. de la librería 9789048191673

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 191,15
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 6,81
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

7.

Walter Rhomberg (Editor), Kurt Hellmann (Editor)
Editorial: Springer (2010)
ISBN 10: 904819167X ISBN 13: 9789048191673
Nuevos Tapa dura Cantidad: 1
Librería
Ergodebooks
(RICHMOND, TX, Estados Unidos de America)
Valoración
[?]

Descripción Springer, 2010. Hardcover. Estado de conservación: New. 2011. Nº de ref. de la librería DADAX904819167X

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 199,05
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 4,25
A Estados Unidos de America
Destinos, gastos y plazos de envío

8.

Editorial: Springer (2010)
ISBN 10: 904819167X ISBN 13: 9789048191673
Nuevos Tapa dura Cantidad: 1
Librería
Valoración
[?]

Descripción Springer, 2010. Estado de conservación: New. Nº de ref. de la librería L9789048191673

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 208,10
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 2,99
De Alemania a Estados Unidos de America
Destinos, gastos y plazos de envío

9.

Kurt Hellmann
Editorial: Springer-Verlag Gmbh Okt 2010 (2010)
ISBN 10: 904819167X ISBN 13: 9789048191673
Nuevos Cantidad: 1
Librería
Valoración
[?]

Descripción Springer-Verlag Gmbh Okt 2010, 2010. Buch. Estado de conservación: Neu. Neuware - Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of patho-logical blood vessels. Razoxane potentiates radiotherapy especially in the treatment of soft tissue sarcomas and gastrointestinal neoplasms. They protect normal tissues against toxic chemicals, e.g. the myocardium against anthra-cyclines or subcutaneous tissue against injuries caused by incidental extravasations of anthra-cyclines. Dexrazoxane is the only drug approved by the FDA/UMEA for the specific purpose of preventing cardiac damage when giving the widely used and effective antitumor anthra-cyclines. The reduction of cardiotoxicity is achieved without response reduction or reducing of time to progression of tumors. While the full analysis of their actions at the molecular level is not yet completely understood, it seems most likely that it is via an inhibition on the topo-isomerase II a. Moreover, the drugs have the ability to chelate several metals including iron, copper or zinc. The protection of normal tissues is nowhere more important than that of brain, and there are indications that the proteins thought to be responsible for the ravages of Alzheimer s disease could be stabilized by one or both these drugs. 243 pp. Englisch. Nº de ref. de la librería 9789048191673

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 199,99
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 12,00
De Alemania a Estados Unidos de America
Destinos, gastos y plazos de envío

10.

Kurt Hellmann
Editorial: Springer-Verlag Gmbh Okt 2010 (2010)
ISBN 10: 904819167X ISBN 13: 9789048191673
Nuevos Cantidad: 1
Librería
Rheinberg-Buch
(Bergisch Gladbach, Alemania)
Valoración
[?]

Descripción Springer-Verlag Gmbh Okt 2010, 2010. Buch. Estado de conservación: Neu. Neuware - Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of patho-logical blood vessels. Razoxane potentiates radiotherapy especially in the treatment of soft tissue sarcomas and gastrointestinal neoplasms. They protect normal tissues against toxic chemicals, e.g. the myocardium against anthra-cyclines or subcutaneous tissue against injuries caused by incidental extravasations of anthra-cyclines. Dexrazoxane is the only drug approved by the FDA/UMEA for the specific purpose of preventing cardiac damage when giving the widely used and effective antitumor anthra-cyclines. The reduction of cardiotoxicity is achieved without response reduction or reducing of time to progression of tumors. While the full analysis of their actions at the molecular level is not yet completely understood, it seems most likely that it is via an inhibition on the topo-isomerase II a. Moreover, the drugs have the ability to chelate several metals including iron, copper or zinc. The protection of normal tissues is nowhere more important than that of brain, and there are indications that the proteins thought to be responsible for the ravages of Alzheimer s disease could be stabilized by one or both these drugs. 243 pp. Englisch. Nº de ref. de la librería 9789048191673

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 199,99
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 17,13
De Alemania a Estados Unidos de America
Destinos, gastos y plazos de envío

Existen otras copia(s) de este libro

Ver todos los resultados de su búsqueda